Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product
- 21 September 2016
- journal article
- research article
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 8 (4) , 417-425
Abstract
A structured benefit-risk assessment (BRA) is critical for drug development and lifecycle management. How to select B-R endpoints, determine weighting for these endpoints, and evaluate uncertainties are key aspects of the B-R decision-making process. In this article, we discuss key considerations on endpoint selection, challenges of double counting and correlated endpoints, and methods that can be used to address these challenges. In addition, we discuss the use of qualitative and quantitative weighting in BRA, techniques useful for weight construction, and weights based on empirical preferences. Potential sources for uncertainties in BRA, the approaches to illustrate and to address these uncertainties are described. Finally, we emphasize that benefit-risk assessment is a continuous process and requires cross-functional efforts.Keywords
This publication has 22 references indexed in Scilit:
- Incorporating patient-preference evidence into regulatory decision makingSurgical Endoscopy, 2015
- Patients’ preferences for osteoporosis drug treatment: a discrete-choice experimentArthritis Research & Therapy, 2014
- Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task ForceValue in Health, 2013
- A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working GroupValue in Health, 2010
- Crohn’s Disease Patients’ Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment EfficacyGastroenterology, 2007
- Global benefit–risk assessment in designing clinical trials and some statistical considerations of the methodPharmaceutical Statistics, 2007
- Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosisJournal of Clinical Epidemiology, 2004
- Users' Guides to the Medical LiteratureXVI. How to Use a Treatment RecommendationJAMA, 1999
- A new proposal for benefit-less-risk analysis in clinical trialsControlled Clinical Trials, 1994
- Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trialsStatistics in Medicine, 1991